CN110267658B - 用sGC刺激剂治疗CNS疾病 - Google Patents

用sGC刺激剂治疗CNS疾病 Download PDF

Info

Publication number
CN110267658B
CN110267658B CN201780080543.0A CN201780080543A CN110267658B CN 110267658 B CN110267658 B CN 110267658B CN 201780080543 A CN201780080543 A CN 201780080543A CN 110267658 B CN110267658 B CN 110267658B
Authority
CN
China
Prior art keywords
pain
compound
pharmaceutically acceptable
syndrome
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780080543.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN110267658A (zh
Inventor
J.琼格
T.W-H.李
R.R.艾扬格
N.R.珀尔
P.格马诺
M.D.里巴德尼拉
K.唐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Di Shan Duo Pharmaceutical Co
Original Assignee
Di Shan Duo Pharmaceutical Co
Cyclerion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Di Shan Duo Pharmaceutical Co, Cyclerion Therapeutics Inc filed Critical Di Shan Duo Pharmaceutical Co
Publication of CN110267658A publication Critical patent/CN110267658A/zh
Application granted granted Critical
Publication of CN110267658B publication Critical patent/CN110267658B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780080543.0A 2016-11-08 2017-11-07 用sGC刺激剂治疗CNS疾病 Active CN110267658B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662419059P 2016-11-08 2016-11-08
US62/419,059 2016-11-08
PCT/US2017/060299 WO2018089328A1 (en) 2016-11-08 2017-11-07 Treatment of cns diseases with sgc stimulators

Publications (2)

Publication Number Publication Date
CN110267658A CN110267658A (zh) 2019-09-20
CN110267658B true CN110267658B (zh) 2024-02-02

Family

ID=60452769

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780080543.0A Active CN110267658B (zh) 2016-11-08 2017-11-07 用sGC刺激剂治疗CNS疾病

Country Status (18)

Country Link
US (4) US11690828B2 (https=)
EP (1) EP3538096B1 (https=)
JP (2) JP7150740B2 (https=)
KR (1) KR102475124B1 (https=)
CN (1) CN110267658B (https=)
AU (2) AU2017359018C1 (https=)
BR (1) BR112019009449A2 (https=)
CA (1) CA3042548A1 (https=)
CL (1) CL2019001256A1 (https=)
EA (1) EA201991147A1 (https=)
ES (1) ES2972711T3 (https=)
IL (1) IL266275B2 (https=)
MA (1) MA46752A (https=)
MX (2) MX2019005342A (https=)
PH (1) PH12019501016A1 (https=)
SG (1) SG10202104865UA (https=)
TW (1) TWI812601B (https=)
WO (1) WO2018089328A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110267949A (zh) * 2016-11-08 2019-09-20 塞科里昂医疗股份有限公司 sGC刺激剂
WO2019055859A1 (en) * 2017-09-14 2019-03-21 Ironwood Pharmaceuticals, Inc. TREATMENT OF METABOLIC SYNDROME BY SGC STIMULATOR
KR20250141845A (ko) 2018-07-11 2025-09-29 티센토 쎄라퓨틱스 인크. 미토콘드리아 장애의 치료를 위한 sGC 자극제의 용도
WO2020150698A1 (en) * 2019-01-18 2020-07-23 The Johns Hopkins University Prevention of anesthetic-induced neurocognitive dysfunction
JP2023505329A (ja) * 2019-12-05 2023-02-08 ザイダス・ライフサイエンシーズ・リミテッド リオシグアトの放出調節医薬組成物
EP4101448B1 (en) 2020-02-07 2026-04-22 Neuroventi Composition comprising rilmenidine compound as active ingredient for treatment of fragile x syndrome or related developmental disability
CN112924573B (zh) * 2021-01-21 2022-01-04 山东英盛生物技术有限公司 一种阿比多尔、利巴韦林、氯喹的hplc-ms/ms检测方法
EP4326268A1 (en) * 2021-04-20 2024-02-28 Tisento Therapeutics Inc. Treatment of cns diseases with sgc stimulators
US20250064799A1 (en) * 2021-12-31 2025-02-27 Tenax Therapeutics, Inc. Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction
JP2026505315A (ja) * 2023-02-03 2026-02-13 アール．ピー．シェーラー テクノロジーズ，エルエルシー 浸透圧医薬カプセル

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007124854A1 (de) * 2006-04-27 2007-11-08 Bayer Healthcare Ag Heterocyclisch substituierte, anellierte pyrazol-derivate und ihre verwendung

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3995631A (en) 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US4203440A (en) 1978-10-23 1980-05-20 Alza Corporation Device having variable volume chamber for dispensing useful agent
US4627850A (en) 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
EP0192963B1 (de) 1985-02-27 1988-07-20 Werkzeugmaschinenfabrik Oerlikon-Bührle AG Schwingungsmesseinrichtung für ein Spiralkegelradgetriebe auf einer Zahnradprüfmaschine
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5324280A (en) 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
JP2928079B2 (ja) 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE19830430A1 (de) 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
CZ302691B6 (cs) 1998-07-08 2011-09-07 Sanofi - Aventis Deutschland GmbH N-Arylamidová sloucenina, zpusob její prípravy, farmaceutický prostredek tuto slouceninu obsahující, tato sloucenina pro použití jako aktivátor a pro použití k terapii nebo profylaxi
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
PT1140012E (pt) 1998-12-17 2004-05-31 Alza Corp Conversao de capsulas de gelatina cheias com liquido em sistemas de libertacao controlada por camadas multiplas
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10216145A1 (de) 2002-04-12 2003-10-23 Bayer Ag Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
BRPI0413363A (pt) 2003-08-04 2006-10-10 Pfizer Prod Inc formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase
BRPI0816382A2 (pt) 2007-09-06 2015-02-24 Merck Sharp & Dohme Composto, composição, e, métodos para ativar a guanilato ciclase solúvel e para tratar ou previnir doenças
WO2009094242A1 (en) 2008-01-24 2009-07-30 Merck & Co., Inc. Angiotensin ii receptor antagonists
AU2009322836B2 (en) 2008-11-25 2013-04-04 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
KR20110133034A (ko) 2009-02-26 2011-12-09 머크 샤프 앤드 돔 코포레이션 가용성 구아닐레이트 시클라제 활성화제
US9284301B2 (en) 2010-03-25 2016-03-15 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
KR20140019004A (ko) 2010-05-27 2014-02-13 머크 샤프 앤드 돔 코포레이션 가용성 구아닐레이트 시클라제 활성화제
EP2632551B1 (en) 2010-10-28 2016-07-06 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
US20180344735A1 (en) 2015-12-14 2018-12-06 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DYSFUNCTION
WO2017108441A1 (en) 2015-12-22 2017-06-29 Universiteit Maastricht Treatment of cognitive impairment with cgc stimulator
WO2017121700A1 (de) 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft 1,3-disubstituierte 1h-pyrazolo[3,4-b]pyridin- derivate und ihre verwendung als stimulatoren der löslichen guanylatcyclase
SI3507291T1 (sl) * 2016-09-02 2021-11-30 Cyclerion Therapeutics, Inc. Kondenzirani biciklični SGS stimulatorji

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007124854A1 (de) * 2006-04-27 2007-11-08 Bayer Healthcare Ag Heterocyclisch substituierte, anellierte pyrazol-derivate und ihre verwendung
US20100004235A1 (en) * 2006-04-27 2010-01-07 Bayer Healthcare Ag Heterocyclic Substituted, Anellated Pyrazole Derivative and its uses

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Acidic triazoles as soluble guanylate cyclase stimulators;Lee R.Roberts et al;《Bioorganic & Medicinal Chemistry Letters》;20110828;第6515-6518页 *
Lee R.Roberts et al.Acidic triazoles as soluble guanylate cyclase stimulators.《Bioorganic & Medicinal Chemistry Letters》.2011,第6515-6518页. *
YC-1 BINDING TO THE BETA SUBUNIT OF SOLUBLE GUANYLYL CYCLASE OVERCOMES ALLOSTERIC INHIBITION BY THE ALPHA SUBUNIT;Rahul Purohit et al;《Biochemistry》;20140114;第101-114页 *
非一氧化氮依赖的可溶性鸟苷酸环化酶激动剂药理作用研究进展;何宗晟等;《国际药学研究杂志》;20130831;第40卷(第4期);第422-426页 *

Also Published As

Publication number Publication date
IL266275A (en) 2019-06-30
KR102475124B1 (ko) 2022-12-08
MA46752A (fr) 2019-09-18
PH12019501016A1 (en) 2019-09-09
US11690828B2 (en) 2023-07-04
JP2019534327A (ja) 2019-11-28
CN110267658A (zh) 2019-09-20
US20250108040A1 (en) 2025-04-03
WO2018089328A8 (en) 2019-03-28
SG10202104865UA (en) 2021-06-29
KR20190094167A (ko) 2019-08-12
TWI812601B (zh) 2023-08-21
ES2972711T3 (es) 2024-06-14
CL2019001256A1 (es) 2019-10-04
EP3538096A1 (en) 2019-09-18
BR112019009449A2 (pt) 2019-07-30
US20190343813A1 (en) 2019-11-14
JP2022160605A (ja) 2022-10-19
TW201822765A (zh) 2018-07-01
MX2019005342A (es) 2019-10-02
EP3538096B1 (en) 2024-02-28
US20230381153A1 (en) 2023-11-30
EA201991147A1 (ru) 2019-11-29
JP7150740B2 (ja) 2022-10-11
AU2017359018C1 (en) 2023-12-21
WO2018089328A1 (en) 2018-05-17
MX2022010852A (es) 2022-09-27
NZ753434A (en) 2025-10-31
IL266275B2 (en) 2023-12-01
IL266275B1 (en) 2023-08-01
CA3042548A1 (en) 2018-05-17
EP3538096C0 (en) 2024-02-28
US20260000653A1 (en) 2026-01-01
AU2023270267A1 (en) 2023-12-07
AU2017359018B2 (en) 2023-08-31
AU2017359018A1 (en) 2019-05-30

Similar Documents

Publication Publication Date Title
CN110267658B (zh) 用sGC刺激剂治疗CNS疾病
JP7628096B2 (ja) 縮合二環式ｓｇｃ刺激剤
CN109476686B (zh) sGC刺激剂的磷前药
HK40013531B (en) Treatment of cns diseases with sgc stimulators
HK40013531A (en) Treatment of cns diseases with sgc stimulators
EA041012B1 (ru) ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ С ПОМОЩЬЮ СТИМУЛЯТОРОВ sGC
BR112019004468B1 (pt) Estimulantes de sgc

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20231026

Address after: Massachusetts

Applicant after: Di Shan Duo Pharmaceutical Co.

Address before: Massachusetts

Applicant before: Cyclerion Therapeutics, Inc.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant